Paul C. Boutros

Paul C. Boutros

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2011 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
HCHanbo Chen
Hanbo Chen
PBPaul C. Boutros
Paul C. Boutros
Visualization of orthogonal (disjoint) or overlapping datasets is a common task in bioinformatics. Few tools exist to automate the generation of extensively-customizable, high-resolution Venn and Euler diagrams in the R statistical environment. To fill this gap we introduce VennDiagram, an R package that enables the automated generation of highly-customizable, high-resolution Venn diagrams with up to four sets and Euler diagrams with up to three sets.

1 April 2018 in Cell
Verified
Journal Article
Open access
KHKuan-Lin Huang
Kuan-Lin Huang
RMR. Jay Mashl
R. Jay Mashl
YWYige Wu
Yige Wu
DRDeborah I. Ritter
Deborah I. Ritter
JWJiayin Wang
Jiayin Wang
FCFeng Chen
Feng Chen
We conducted the largest investigation of predisposition variants in cancer to date, discovering 853 pathogenic or likely pathogenic variants in 8% of 10,389 cases from 33 cancer types. Twenty-one genes showed single or cross-cancer associations, including novel associations of SDHA in melanoma and PALB2 in stomach adenocarcinoma. The 659 predisposition variants and 18 additional large deletions in tumor suppressors, including ATM, BRCA1, and NF1, showed low gene expression and frequent (43%) loss of heterozygosity or biallelic two-hit events. We also discovered 33 such variants in oncogenes, including missenses in MET, RET, and PTPN11 associated with high gene expression. We nominated 47 additional predisposition variants from prioritized VUSs supported by multiple evidences involving case-control frequency, loss of heterozygosity, expression effect, and co-localization with mutations and modified residues. Our integrative approach links rare predisposition variants to functional consequences, informing future guidelines of variant classification and germline genetic testing in cancer.

14 January 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
VBVinayak Bhandari
Vinayak Bhandari
CHChristianne Hoey
Christianne Hoey
LLLydia Y. Liu
Lydia Y. Liu
ELEmilie Lalonde
Emilie Lalonde
JRJessica Ray
Jessica Ray
RBRobert G. Bristow
Robert G. Bristow

9 January 2017 in Nature
Verified
Journal Article
Closed access
PDF file
MFMichael Fraser
Michael Fraser
VSVeronica Y. Sabelnykova
Veronica Y. Sabelnykova
TYTakafumi N. Yamaguchi
Takafumi N. Yamaguchi
LHLawrence E. Heisler
Lawrence E. Heisler
JLJulie Livingstone
Julie Livingstone
PBPaul C. Boutros
Paul C. Boutros

8 January 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SCSujun Chen
Sujun Chen
GZGuanghui Zhu
Guanghui Zhu
YYYue Yang
Yue Yang
FWfubo wang
fubo wang
YXYu-Tian Xiao
Yu-Tian Xiao
SRShancheng Ren
Shancheng Ren

15 May 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DBDalia Barsyte-Lovejoy
Dalia Barsyte-Lovejoy
SLSuzanne K. Lau
Suzanne K. Lau
PBPaul C. Boutros
Paul C. Boutros
FKFereshteh Khosravi
Fereshteh Khosravi
IJIgor Jurisica
Igor Jurisica
LPLinda Z. Penn
Linda Z. Penn
The product of the MYC oncogene is widely deregulated in cancer and functions as a regulator of gene transcription. Despite an extensive profile of regulated genes, the transcriptional targets of c-Myc essential for transformation remain unclear. In this study, we show that c-Myc significantly induces the expression of the H19 noncoding RNA in diverse cell types, including breast epithelial, glioblastoma, and fibroblast cells. c-Myc binds to evolutionarily conserved E-boxes near the imprinting control region to facilitate histone acetylation and transcriptional initiation of the H19 promoter. In addition, c-Myc down-regulates the expression of insulin-like growth factor 2 (IGF2), the reciprocally imprinted gene at the H19/IGF2 locus. We show that c-Myc regulates these two genes independently and does not affect H19 imprinting. Indeed, allele-specific chromatin immunoprecipitation and expression analyses indicate that c-Myc binds and drives the expression of only the maternal H19 allele. The role of H19 in transformation is addressed using a knockdown approach and shows that down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. This work indicates that c-Myc induction of the H19 gene product holds an important role in transformation. (Cancer Res 2006; 66(10): 5330-7)